ANAB241220C7500
- 0.00
- 0.000.00%
AnaptysBio Newsroom
Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating, Maintains Target Price $20
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $36
JP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $36
Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating, Announces Target Price $20
Stifel Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $41
Stifel Nicolaus Sticks to Their Buy Rating for AnaptysBio (ANAB)
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), AnaptysBio (ANAB) and US Physical Therapy (USPH)
UBS Adjusts AnaptysBio Price Target to $18 From $33, Maintains Neutral Rating
AnaptysBio Is Maintained at Overweight by Wells Fargo
Guggenheim Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $36
Wells Fargo Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $40
Express News | AnaptysBio Inc : Leerink Partners Cuts Target Price to $32 From $45
AnaptysBio's Atopic Dermatitis Trial of BTLA Agonist Misses Endpoints
AnaptysBio Discontinues ANB032 Development After Phase 2a Trial Fails to Meet Efficacy Endpoints
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Sector Update: Health Care Stocks Softer Late Afternoon
Sector Update: Health Care
Top Midday Decliners
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $32
AnaptysBio (ANAB) Receives a Buy From TD Cowen